Trulieve ($TRLV) Stock Hub: The Medical Business After the NYSE Listing

01The investment case after the NYSE listing

Trulieve is now a U.S.-domiciled, NYSE-listed medical cannabis operator. Its economic exposure is broader than its consolidated revenue: the medical platform remains consolidated, while the retained Harvest investment carries exposure to mixed medical and adult-use markets. Understanding that separation is the starting point for reading $TRLV.

The established business combines cultivation, processing, branded products and direct retail distribution. That integration supports product availability and margins, but requires facilities, inventory, compliance spending and local operating licenses. Florida remains the center of gravity; Georgia offers a nearer-term expansion path, while Texas remains conditional.

The constructive case depends on medical revenue, cash conversion and disciplined deployment of capital. The cautious case rests on pricing pressure, concentration, expensive financing and unresolved historical taxes. Exchange access can improve investability; it does not by itself generate sales or settle those obligations.

Investor presentation · September 2026, pp. 8–15

02What changed: Harvest is outside consolidation

On June 3, 2026, Trulieve lost control of Harvest Enterprises and deconsolidated its mixed-use operations. Some business transfers remain subject to regulatory approval. The company retained non-voting, non-participating units representing a 90% equity interest, accounted for using the equity method. These units currently carry no voting, dividend or dissolution rights and do not confer control. Conversion into participating common units requires the NYSE to permit consolidation of U.S. non-medical marijuana businesses.

The independent investor appoints two of Harvest’s three managers; Trulieve appoints one. The September presentation lists Harvest operations in Arizona, Connecticut, Maryland and Ohio, with 34 dispensaries and 0.5 million square feet of production. Those stores must not be added to Trulieve’s consolidated store base when comparing productivity.

At June 30, the retained investment was carried at $152.5 million and the management-services receivable at $22.9 million. The filing identifies combined maximum exposure of approximately $175.4 million and states that Trulieve had not guaranteed Harvest’s debt or committed additional financial support. The services agreement reimburses costs plus a 5% margin and a fixed quarterly fee; either party can terminate with 90 days’ notice.

The $403.3 million deconsolidation loss is primarily non-cash, but the transaction also removed $58.4 million of cash from consolidation. “Non-cash loss” therefore does not mean the group’s reported cash balance was unaffected.

Form 10-Q · June 30, 2026

03Operating footprint and Florida concentration

The September investor presentation reports 207 consolidated medical dispensaries and 3.5 million square feet of cultivation and processing capacity. Its geographic snapshot comprises Florida 170 stores, Pennsylvania 21, West Virginia 10 and Georgia 6. Dunwoody is presented separately as the next Georgia addition; this hub keeps the dated 207-store baseline rather than mixing snapshots.

Florida represents approximately 82.1% of the stores in that snapshot, calculated as 170/207. This is a store-count concentration measure, not a revenue share. Dense local coverage and cultivation scale can support execution, while dependence on one medical program makes patient growth, pricing and competitive promotions important to the whole group.

Trulieve reports 78% customer retention in medical-only markets in Q2 and 1.1 million rewards members across the retail platform at June 30. These company metrics describe reach and engagement; they are not equivalent to unique active patients or guaranteed recurring revenue.

Investor presentation · September 2026, pp. 8–13

04Georgia, Pennsylvania and the next markets

Georgia’s expanded medical program launched on July 1, 2026. Trulieve’s presentation describes additional product formats and distribution through independent pharmacies. This creates more routes to reach patients, although the resulting sales and margin contribution must still be demonstrated in reported results. The September 4 release announces the Dunwoody location and a September 10 grand-opening celebration at 9:30 a.m. Eastern; the release already describes the store as open.

Pennsylvania combines 21 company dispensaries with wholesale distribution. Management says its products reached 85% of Pennsylvania dispensaries during Q2. That is distribution reach, not market share. Potential adult-use legislation is a separate policy scenario, with implications for the structure used to keep the consolidated business medical-only.

Texas and Alabama are described as conditional license opportunities. Management anticipates final Texas approval as soon as 2026, but this is an expectation, not a granted final license or an announced revenue start. Build-out spending, approval timing and patient adoption determine whether these opportunities become material.

Investor presentation · September 2026, pp. 19–21; Dunwoody release below

05Q2 results: reported and medical-only are different

Reported Q2 revenue was $271.0 million, compared with $302.1 million a year earlier and $286.8 million in Q1. The June 3 change in consolidation is the main reason these comparisons are not like-for-like. The filing also identifies pricing pressure in mature markets. Approximately 94% of reported Q2 sales were retail.

The September presentation supplies a medical-only comparison: Q1 revenue of $214.0 million and Q2 revenue of $222.3 million, with gross profit of $137.9 million and $140.1 million respectively. Revenue increased about 3.9% sequentially on that company-presented basis, while the rounded medical gross margin fell from 64% to 63%. These are pro forma medical figures, not the GAAP consolidated totals.

The distinction matters for Q3. A reported revenue figure around the medical baseline can be consistent with management’s outlook even if it is below the mixed-perimeter Q2 total. Simply labeling that gap an organic sales decline would be misleading.

Form 10-Q · June 30, 2026

06Cash generation and the quality of free cash flow

Q2 operating cash flow was $53.1 million. After $21.0 million of capital expenditures, company-defined free cash flow was $32.1 million. For the first half, operating cash flow was $108.8 million and capital expenditures $34.5 million; the company reports approximately $74.4 million of free cash flow, with rounding affecting the displayed subtraction.

Free cash flow is a non-GAAP measure calculated as operating cash flow less capital expenditures. It does not deduct debt principal repayments, acquisition spending or every potential tax settlement. The cash-flow statement includes a $61.0 million first-half adjustment for uncertain tax position liabilities, so operating cash generation should be assessed together with the tax notes.

Cash increased from $255.5 million at year-end to $325.4 million at June 30. That increase was not funded by operations alone: the first half included $60.7 million of borrowing proceeds and $58.4 million of cash removed with Harvest. The balance sheet has liquidity, but the headline cash figure cannot be treated as cash freely available for shareholders after all claims.

Form 10-Q · June 30, 2026

07Debt, leases and maturities

At June 30, private-placement notes had $200.0 million of principal, a 10.5% coupon and a December 17, 2030 maturity. Other notes totaled $94.6 million of principal, mostly property-backed financing. Their combined carrying amount was approximately $289.4 million after issuance costs and discounts. This explains the $289 million “debt” figure in the investor presentation; it excludes other financing-like obligations.

Principal only; excludes lease and construction-finance payments and interest. Source: 10-Q, Note 6.

Separately, the balance sheet carries approximately $120.8 million of construction-finance liabilities, $70.0 million of finance-lease liabilities and $97.1 million of operating-lease liabilities, including current portions. These are distinct from the notes above. Comparing $325.4 million of cash only with $289.4 million of notes gives a narrow cash-surplus measure, not a debt-free balance sheet.

The company reports compliance with its operating and financial covenants at June 30. The 2030 maturity reduces immediate refinancing pressure, while the coupon and the 2028 mortgage concentration remain relevant to cash allocation.

Form 10-Q · June 30, 2026

08Tax position: 2026 treatment and historical exposure

The Q2 tax note distinguishes the current year from past disputes. Trulieve states that its 2026 medical tax positions satisfy the accounting recognition threshold following the April federal developments; it did not record current-period uncertain tax positions for medical activities. That is the company’s accounting judgment, not confirmation that earlier-year liabilities have been forgiven.

The June 30 balance sheet includes $598.2 million of net uncertain-tax-position liabilities, of which $583.1 million relates to its challenge to Section 280E. The balance includes $87.0 million of accrued interest. The filing separately identifies $65.1 million of previous tax payments claimed as overpayments; these should not be added to cash as if a new refund were guaranteed.

IRS examinations remain relevant. The filing describes proposed assessments and protests before the IRS Independent Office of Appeals. Proposed penalties of approximately $38.1 million are not included in the uncertain-tax-position balance; the company disputes them. The reduction in the reported liability also reflects deconsolidation, rather than a blanket resolution of the controversy.

Retroactive relief is therefore potential upside, not an earned receivable or recurring operating profit. A future reversal would need its own legal and accounting basis and could be a one-time item. Conversely, adverse settlement terms could create cash needs not captured by an EBITDA multiple.

Form 10-Q · June 30, 2026

09Management outlook: what must happen in H2

The September presentation expects Q3 reported revenue to be comparable with approximately $222 million of Q2 medical revenue. It targets at least $225 million of 2026 operating cash flow, reduced from $250 million following deconsolidation, and capital expenditures of up to $95 million, increased from $85 million for growth-market investment.

Using reported first-half operating cash flow of $108.8 million, reaching $225 million would require at least approximately $116.2 million in H2. This is a simple Merlintrader calculation, not separate company guidance. It focuses attention on conversion of medical earnings into cash, timing of working capital and deployment in new markets.

There is no verified Q3 earnings date in the company event sources checked on September 9. The September 29 Roth investor meetings are an announced communication opportunity, not an earnings release. Neither Texas approval in 2026 nor a broader federal order in 2026 should be presented as a scheduled, certain event.

Investor presentation · September 2026, pp. 15 and 23

10Share capital, dilution and buybacks

The 10-Q cover reports 170,158,916 subordinate voting shares and 22,406,386 multiple-voting-share equivalents at July 31, for 192,565,302 shares on an as-converted basis. This differs from the June 30 balance-sheet count of 192,382,935. Finviz displays roughly 169.98 million shares, closer to the subordinate class alone; it should not silently replace the total economic denominator.

The June authorization permits repurchases up to the lesser of $50 million or 8,495,038 subordinate voting shares and is expected to expire June 16, 2027. The 10-Q reports no repurchases through June 30. Authorization is optional capacity, not completed demand or a guaranteed reduction of share count.

Potential dilution remains despite the buyback. At June 30 there were approximately 5.3 million options and 7.8 million unvested RSUs; the filing excludes about 13.4 million potentially dilutive shares from loss-per-share calculations because they would be antidilutive. Grant conditions, exercise prices and vesting matter: these figures should not simply be added again to every pro forma share estimate.

Form 10-Q · June 30, 2026

11Leadership, governance and insider activity

The September presentation identifies founder Kim Rivers as chairman and CEO, Jan Reese as CFO and Peter Healy as lead director. The August 11 redomiciliation to Delaware is completed; the subordinate shares continue to trade as TRLV. Potential eligibility for broader index inclusion, cited by management, is not confirmation of admission to any specific index.

The June 26 Form 4 records a sale of 136,811 subordinate shares by Rivers at a weighted-average $8.756, under a pre-existing Rule 10b5-1 plan. Its notes confirm completion of the first tranche totaling 1,699,007 shares. The filing also lists multiple-voting holdings, so the direct subordinate-share balance alone is not her total economic holding.

The accompanying release announced an intention to terminate the remaining plan on August 11 before the second tranche. This hub does not convert that earlier intention into independently verified completion. The disclosed June sales are neither open-market purchases nor proof of an undisclosed judgment about future results.

SEC Form 4 · June 26, 2026; leadership and redomiciliation links below

12Market snapshot and valuation limits

IBKR reports $12.28 at 11:23:06 a.m. Eastern on September 9, 2026, with a prior close of $12.43. This is an intraday observation, not the closing price. An independent Finviz snapshot at 11:22 a.m. showed $12.27, consistent with a small intervening price change. The figures are dated observations and do not update with the embedded chart.

Applying $12.28 to the July 31 as-converted count of 192,565,302 gives an illustrative equity value of approximately $2.365 billion. This combines a current quote with the latest verified filing count, not a live fully diluted capitalization. Changes after that count date are not incorporated.

Finviz displays a $18.18 consensus target, 162.60 million float and short interest of 0.82% of float in the September 9 snapshot. These are provider-reported aggregates, not company guidance; the underlying settlement date of the short position is not supplied in the snapshot. The target is opinion and should not be treated as a valuation conclusion.

A conventional trailing revenue or EBITDA multiple mixes the old and new operating perimeter. A useful valuation must distinguish medical operating cash flows, the restricted Harvest interest, leases and construction financing, share dilution and the tax exposure. This hub therefore does not assign a price target or imply that an aggregator multiple values all those components correctly.

Finviz snapshot · September 9, 2026; price cross-check: IBKR

13Federal policy and the competitive landscape

The September presentation states that Trulieve’s consolidated state-licensed medical facilities are DEA registered. This updates the earlier April and August language about applications. It is an issuer statement in the current investor materials, not an independently inspected registration certificate for every location.

The broader marijuana rescheduling proceeding is separate from the medical pathway. The DEA procedural page checked on September 9 does not establish a new final broad order. Management’s expectation of a 2026 outcome remains forward-looking. Banking access, state licensing, product restrictions and legacy tax disputes cannot be assumed solved by the ticker change.

Trulieve competes locally for patients, locations, product quality, price and brand loyalty. U.S. operators are the closer operating comparison; Canadian-listed cannabis groups can have very different geography, international exposure or beverage businesses. Sector-wide share-price movement alone does not demonstrate equal exposure to U.S. medical reform. The linked Cannabis Stocks Hub provides that wider context.

DEA proceeding; company registration statement: September presentation, p. 14

14Catalyst calendar

Dates refer to announced events or contractual schedules, not forecasts of share-price movement. Texas approval, broader rescheduling and tax relief remain undated conditional developments.

September event announcement; debt and buyback schedules: Q2 10-Q

15Evergreen timeline

September investor presentation and linked company releases

16Bull, base and bear scenarios

These scenarios organize the operating and financial sensitivities. They are not probability-weighted forecasts and carry no implied return.

Form 10-Q · June 30, 2026

17What would strengthen or weaken the case

Positive evidence to watch: medical revenue holding the Q2 baseline, margins that withstand price competition, H2 operating cash flow consistent with the revised full-year target, successful Georgia distribution, final licenses before major expansion assumptions, and clearer tax outcomes supported by official documents.

Warning signs: medical revenue erosion masked by changing consolidation, recurring adjustments that overstate underlying profitability, cash requirements from tax disputes, increased financing costs, lower recoverability of the Harvest investment or receivable, and buybacks competing with necessary capital expenditure.

The first full post-Harvest reporting period is more informative than comparing today’s headline sales with the former mixed-use group. Durable progress should appear in cash flow and economic returns after financing costs, not just in a higher exchange profile.

Form 10-Q · June 30, 2026

18Merlintrader assessment

TRLV offers a more focused listed medical-cannabis business after the NYSE listing and Delaware redomiciliation. It has an established retail base and demonstrated operating cash generation. Georgia expansion and the medical-only revenue bridge make the next reporting periods worth following closely.

The complete picture still includes a restricted Harvest investment, material historical tax exposure and obligations beyond the headline notes balance. The central question is whether the medical platform can deliver the revised cash target and fund growth while keeping those claims manageable. That is the evidence this hub will track.

Form 10-Q · June 30, 2026